Trial Profile
RCT comparing the levonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation in women suffering from menorrhagia (MIRA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Levonorgestrel (Primary)
- Indications Menorrhagia
- Focus Therapeutic Use
- Acronyms MIRA
- 10 Jul 2021 Results evaluating the costs and non-inferiority of a strategy starting with the LNG-IUS compared to endometrial ablation in the treatment of heavy menstrual bleeding, published in the BJOG: An International Journal of Obstetrics and Gynaecology
- 11 Aug 2020 Status changed from not yet recruiting to completed, as per results published in the American Journal of Obstetrics and Gynecology
- 11 Aug 2020 Primary endpoint (blood loss at 24 months) has not been met, as per Results published in the American Journal of Obstetrics and Gynecology